创新药板块波动加大，还能涨吗？三大医药基金经理最新解读

Core Viewpoint - The innovative pharmaceutical sector has shown remarkable performance this year, driven by favorable policies, improved fundamentals, and valuation recovery, leading to increased investor confidence in Chinese innovative drug companies [3][4][5]. Group 1: Drivers of Performance - The outstanding performance of the innovative drug sector is attributed to a positive fundamental outlook, strong policy support, and accelerated internationalization of the industry [4][5]. - Key factors include robust policy measures such as the introduction of new healthcare payment systems and the establishment of a supportive environment for innovative drug development [5][6]. - The sector has seen a surge in business development (BD) activities, with transaction volumes exceeding $60 billion in the first half of the year, indicating a significant increase in collaboration with international companies [5]. Group 2: Competitive Landscape Changes - The dual impact of BD and healthcare policies is reshaping the competitive landscape of the Chinese innovative drug industry, leading to accelerated differentiation and improved global competitiveness among domestic companies [8][9]. - The establishment of a new payment directory and the introduction of a multi-channel payment system are expected to enhance the market access for over 100 innovative drugs, significantly increasing the healthcare expenditure on innovative drugs by 3.9 times by 2024 compared to 2020 [9]. Group 3: Stock Selection Insights - Investment strategies focus on identifying companies with significant growth potential, high industry attractiveness, and strong management integrity [10][11]. - The emphasis is on tracking key pipelines and entering positions when companies are undervalued, aiming to capitalize on market recognition as catalysts are validated [10][11]. Group 4: Future Market Outlook - The innovative drug sector is currently in the early stages of a rebound, with substantial growth potential as the market for innovative drugs in China is still underdeveloped compared to developed countries [13][14]. - The focus is shifting towards performance-driven market dynamics, where companies that can consistently deliver valuable innovations and effectively convert them into commercial success will gain market attention [14]. Group 5: Areas of Opportunity - Beyond innovative drugs, sectors such as innovative medical devices and upstream life sciences are also seen as promising areas for investment, with significant domestic market potential [16]. - Specific fields like ADC, dual antibodies, and gene therapy are highlighted as having substantial growth prospects, with a notable increase in the number of competitive projects emerging from China [16].